Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIc trial of NL005 in acute myocardial infarction
CTR20262169Phase 2Active
- Sponsor
- Northland Biotech
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of gletimbetasin in myocardial infarction (MI), sponsored by Northland Biotech. Started Jul 2026; status: active.
02
Drugs
gletimbetasin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on CTR20262169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262169.